Research progress of vimentin in lupus nephritis_West China Medical Journal

Authors：

LUO Huimin ,  LIAO Xiangping , KUANG Xuling

Department of Renal Rheumatology and Immunology, Chenzhou Hospital Affiliated to University of South China (Chenzhou First People’s Hospital), Chenzhou, Hunan 423000, P. R. China;

Corresponding author：

LIAO Xiangping, Email: 783702705@qq.com

Keywords：

Vimentin; Lupus nephritis; Tubulointerstitial nephritis; Epithelial-mesenchymal transition

DOI：

10.7507/1002-0179.202004194

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Systemic lupus erythematosus is an autoimmune disease involving multiple organs of the body. Lupus nephritis is one of the most serious organ manifestations of systemic lupus erythematosus. Vimentin, a member of the intermediate filament protein family, is involved in the pathogenesis of many autoimmune diseases, including lupus nephritis. More and more studies have shown that vimentin plays an important role in the pathogenesis of lupus nephritis, and has an important influence on the disease development, treatment and prognosis of lupus nephritis. This review focuses on the structure, function and post-translational modification of vimentin, the relationship between vimentin and the pathogenesis of lupus nephritis, and the significance of vimentin expression levels in renal tissues, serum and urine, in order to provide theoretical basis for future mechanism research and clinical application.

Citation： LUO Huimin, LIAO Xiangping, KUANG Xuling. Research progress of vimentin in lupus nephritis. West China Medical Journal, 2021, 36(7): 969-973. doi: 10.7507/1002-0179.202004194 Copy

1.	Narváez J. Systemic lupus erythematosus 2020. Med Clin (Barc), 2020, 155(11): 494-501.
2.	Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis, 2020, 76(2): 265-281.
3.	Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis. Nat Rev Dis Primers, 2020, 6(1): 7.
4.	Raimbourg Q, Daugas É. Lupus nephritis. Nephrol Ther, 2019, 15(3): 174-189.
5.	Musaelyan A, Lapin S, Nazarov V, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev, 2018, 17(9): 926-934.
6.	Sharma P, Alsharif S, Fallatah A, et al. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells, 2019, 8(5): 497.
7.	Strouhalova K, Přechová M, Gandalovičová A, et al. Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel), 2020, 12(1): 184.
8.	Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem, 1994, 63: 345-382.
9.	Goldie KN, Wedig T, Mitra AK, et al. Dissecting the 3-D structure of vimentin intermediate filaments by cryo-electron tomography. J Struct Biol, 2007, 158(3): 378-385.
10.	Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation, 2014, 21(4): 333-344.
11.	Ivaska J, Pallari HM, Nevo J, et al. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res, 2007, 313(10): 2050-2062.
12.	Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration. F1000Res, 2018, 7: F1000 Faculty Rev-1796.
13.	李国炜, 李海洋. 波形蛋白的生物学功能及相关病理的研究进展. 医学综述, 2018, 24(7): 1273-1278.
14.	Patteson AE, Vahabikashi A, Goldman RD, et al. Mechanical and non-mechanical functions of filamentous and non-filamentous vimentin. Bioessays, 2020, 42(11): e2000078.
15.	Danielsson F, Peterson MK, Caldeira Araújo H, et al. Vimentin diversity in health and disease. Cells, 2018, 7(10): 147.
16.	Ebrahimi-Rad M, Khatami S, Akhbari H, et al. Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients. Reumatologia, 2020, 58(6): 350-356.
17.	Kinloch AJ, Kaiser Y, Wolfgeher D, et al. In situ humoral immunity to vimentin in HLA-DRB1*03+ patients with pulmonary sarcoidosis. Front Immunol, 2018, 9: 1516.
18.	Alessandri C, Agmon-Levin N, Conti F, et al. Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. Immunol Res, 2017, 65(2): 524-531.
19.	Mortensen JH, van Haaften WT, Karsdal MA, et al. The citrullinated and MMP-degraded vimentin biomarker (VICM) predicts early response to anti-TNFα treatment in Crohn’s disease. J Clin Gastroenterol, 2021, 55(1): 59-66.
20.	Surolia R, Li FJ, Wang Z, et al. Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury. JCI Insight, 2019, 4(7): e123253.
21.	Divanyan T, Acosta E, Patel D, et al. Anti-vimentin antibodies in transplant and disease. Hum Immunol, 2019, 80(8): 602-607.
22.	Broder A, Mowrey WB, Khan HN, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Semin Arthritis Rheum, 2018, 47(4): 545-551.
23.	Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol, 2015, 35(5): 455-464.
24.	Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol, 2011, 186(3): 1849-1860.
25.	Winchester R, Wiesendanger M, Zhang HZ, et al. Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8⁺ T cell β-chain clonotypes in progressive lupus nephritis. Arthritis Rheum, 2012, 64(5): 1589-600.
26.	Kinloch AJ, Chang A, Ko K, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol, 2014, 66(12): 3359-3370.
27.	Goilav B, Putterman C. The role of anti-DNA antibodies in the development of lupus nephritis: a complementary, or alternative, viewpoint?. Semin Nephrol, 2015, 35(5): 439-443.
28.	André-Schwartz J, Datta SK, Shoenfeld Y, et al. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol, 1984, 31(2): 261-271.
29.	Bruschi M, Sinico RA, Moroni G, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol, 2014, 25(11): 2483-2498.
30.	Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int J Exp Pathol, 2011, 92(3): 143-150.
31.	Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol, 2011, 7(12): 684-696.
32.	Cao YH, Lv LL, Zhang X, et al. Urinary vimentin mRNA as a potential novel biomarker of renal fibrosis. Am J Physiol Renal Physiol, 2015, 309(6): F514-F522.
33.	Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair, 2011, 4: 11.
34.	Muchaneta-Kubara EC, el Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant, 1997, 12(5): 904-915.
35.	Bob FR, Gluhovschi G, Herman D, et al. Histological, immunohistochemical and biological data in assessing interstitial fibrosis in patients with chronic glomerulonephritis. Acta Histochem, 2008, 110(3): 196-203.
36.	Davidson A. Editorial: autoimmunity to vimentin and lupus nephritis. Arthritis Rheumatol, 2014, 66(12): 3251-3254.
37.	Rocha LP, Xavier SC, Helmo FR, et al. Epithelial-mesenchymal transition in pediatric nephropathies. Pathol Res Pract, 2016, 212(12): 1157-1166.
38.	王艳, 王德琴, 缪娴静. 系统性红斑狼疮肾炎患者中波形蛋白的水平变化及临床意义. 临床肾脏病杂志, 2019, 19(8): 618-620.
39.	Li Y, Jia R, Liu Y, et al. Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus, 2020, 29(3): 239-247.
40.	Kinloch AJ, Cascino MD, Dai J, et al. Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus, 2020, 29(6): 569-577.
41.	Anania VG, Yu K, Pingitore F, et al. Discovery and qualification of candidate urinary biomarkers of disease activity in lupus nephritis. J Proteome Res, 2019, 18(3): 1264-1277.

1. Narváez J. Systemic lupus erythematosus 2020. Med Clin (Barc), 2020, 155(11): 494-501.
2. Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis, 2020, 76(2): 265-281.
3. Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis. Nat Rev Dis Primers, 2020, 6(1): 7.
4. Raimbourg Q, Daugas É. Lupus nephritis. Nephrol Ther, 2019, 15(3): 174-189.
5. Musaelyan A, Lapin S, Nazarov V, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev, 2018, 17(9): 926-934.
6. Sharma P, Alsharif S, Fallatah A, et al. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells, 2019, 8(5): 497.
7. Strouhalova K, Přechová M, Gandalovičová A, et al. Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel), 2020, 12(1): 184.
8. Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem, 1994, 63: 345-382.
9. Goldie KN, Wedig T, Mitra AK, et al. Dissecting the 3-D structure of vimentin intermediate filaments by cryo-electron tomography. J Struct Biol, 2007, 158(3): 378-385.
10. Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation, 2014, 21(4): 333-344.
11. Ivaska J, Pallari HM, Nevo J, et al. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res, 2007, 313(10): 2050-2062.
12. Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration. F1000Res, 2018, 7: F1000 Faculty Rev-1796.
13. 李国炜, 李海洋. 波形蛋白的生物学功能及相关病理的研究进展. 医学综述, 2018, 24(7): 1273-1278.
14. Patteson AE, Vahabikashi A, Goldman RD, et al. Mechanical and non-mechanical functions of filamentous and non-filamentous vimentin. Bioessays, 2020, 42(11): e2000078.
15. Danielsson F, Peterson MK, Caldeira Araújo H, et al. Vimentin diversity in health and disease. Cells, 2018, 7(10): 147.
16. Ebrahimi-Rad M, Khatami S, Akhbari H, et al. Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients. Reumatologia, 2020, 58(6): 350-356.
17. Kinloch AJ, Kaiser Y, Wolfgeher D, et al. In situ humoral immunity to vimentin in HLA-DRB1*03+ patients with pulmonary sarcoidosis. Front Immunol, 2018, 9: 1516.
18. Alessandri C, Agmon-Levin N, Conti F, et al. Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. Immunol Res, 2017, 65(2): 524-531.
19. Mortensen JH, van Haaften WT, Karsdal MA, et al. The citrullinated and MMP-degraded vimentin biomarker (VICM) predicts early response to anti-TNFα treatment in Crohn’s disease. J Clin Gastroenterol, 2021, 55(1): 59-66.
20. Surolia R, Li FJ, Wang Z, et al. Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury. JCI Insight, 2019, 4(7): e123253.
21. Divanyan T, Acosta E, Patel D, et al. Anti-vimentin antibodies in transplant and disease. Hum Immunol, 2019, 80(8): 602-607.
22. Broder A, Mowrey WB, Khan HN, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Semin Arthritis Rheum, 2018, 47(4): 545-551.
23. Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol, 2015, 35(5): 455-464.
24. Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol, 2011, 186(3): 1849-1860.
25. Winchester R, Wiesendanger M, Zhang HZ, et al. Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8⁺ T cell β-chain clonotypes in progressive lupus nephritis. Arthritis Rheum, 2012, 64(5): 1589-600.
26. Kinloch AJ, Chang A, Ko K, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol, 2014, 66(12): 3359-3370.
27. Goilav B, Putterman C. The role of anti-DNA antibodies in the development of lupus nephritis: a complementary, or alternative, viewpoint?. Semin Nephrol, 2015, 35(5): 439-443.
28. André-Schwartz J, Datta SK, Shoenfeld Y, et al. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol, 1984, 31(2): 261-271.
29. Bruschi M, Sinico RA, Moroni G, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol, 2014, 25(11): 2483-2498.
30. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int J Exp Pathol, 2011, 92(3): 143-150.
31. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol, 2011, 7(12): 684-696.
32. Cao YH, Lv LL, Zhang X, et al. Urinary vimentin mRNA as a potential novel biomarker of renal fibrosis. Am J Physiol Renal Physiol, 2015, 309(6): F514-F522.
33. Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair, 2011, 4: 11.
34. Muchaneta-Kubara EC, el Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant, 1997, 12(5): 904-915.
35. Bob FR, Gluhovschi G, Herman D, et al. Histological, immunohistochemical and biological data in assessing interstitial fibrosis in patients with chronic glomerulonephritis. Acta Histochem, 2008, 110(3): 196-203.
36. Davidson A. Editorial: autoimmunity to vimentin and lupus nephritis. Arthritis Rheumatol, 2014, 66(12): 3251-3254.
37. Rocha LP, Xavier SC, Helmo FR, et al. Epithelial-mesenchymal transition in pediatric nephropathies. Pathol Res Pract, 2016, 212(12): 1157-1166.
38. 王艳, 王德琴, 缪娴静. 系统性红斑狼疮肾炎患者中波形蛋白的水平变化及临床意义. 临床肾脏病杂志, 2019, 19(8): 618-620.
39. Li Y, Jia R, Liu Y, et al. Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus, 2020, 29(3): 239-247.
40. Kinloch AJ, Cascino MD, Dai J, et al. Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus, 2020, 29(6): 569-577.
41. Anania VG, Yu K, Pingitore F, et al. Discovery and qualification of candidate urinary biomarkers of disease activity in lupus nephritis. J Proteome Res, 2019, 18(3): 1264-1277.

West China Medical Journal

Research progress of vimentin in lupus nephritis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content